| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 1.717 | 42.450 | 34.472 | 18.185 | 24.748 | 17.609 | 18.222 | 23.622 | 79.283 |
| Total Income - EUR | - | 1.717 | 42.991 | 34.627 | 18.780 | 24.930 | 18.965 | 18.387 | 23.805 | 79.352 |
| Total Expenses - EUR | - | 848 | 1.513 | 1.709 | 1.252 | 2.051 | 1.431 | 1.805 | 2.155 | 1.991 |
| Gross Profit/Loss - EUR | - | 869 | 41.478 | 32.918 | 17.528 | 22.880 | 17.535 | 16.582 | 21.650 | 77.361 |
| Net Profit/Loss - EUR | - | 817 | 40.189 | 31.884 | 16.966 | 22.158 | 16.977 | 16.115 | 18.255 | 65.231 |
| Employees | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Oncoline Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 0 | 0 | 0 | 0 | 0 | 0 | 942 | 403 | 0 |
| Current Assets | - | 1.565 | 41.827 | 32.463 | 18.003 | 23.383 | 17.685 | 15.982 | 19.121 | 67.553 |
| Inventories | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | 644 | 750 | 1.335 | 13.705 | 3.368 | 429 | 15.568 | 12.923 | 58.287 |
| Cash | - | 921 | 41.077 | 31.128 | 4.298 | 20.015 | 17.256 | 414 | 6.198 | 9.266 |
| Shareholders Funds | - | 862 | 40.241 | 31.936 | 17.016 | 22.208 | 17.026 | 16.359 | 18.304 | 65.280 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 704 | 1.585 | 528 | 987 | 1.175 | 659 | 566 | 1.219 | 2.273 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Oncoline Srl